MedTrace Logo

GABA-glutamate Interactions and Psychosis

NCT00611572 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2022-07-22

No results posted yet for this study

Summary

This study investigates the interactions between NMDA (N-Methyl-D-aspartic acid) antagonism and GABA (gamma-aminobutyric acid) system as it relates to cognitive function assessed by ERPs (event-related potentials) in healthy volunteers.

Conditions

  • Cognitive Dysfunction

Interventions

DRUG

iomazenil

Given as IV infusion

DRUG

iomazenil

saline IV infusion

Sponsors & Collaborators

  • National Alliance for Research on Schizophrenia and Depression

    collaborator OTHER

  • Yale University

    lead OTHER

Principal Investigators

  • Mohini Ranganathan, M.D. · Yale School of Medicine, Associate Professor

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2018-10-02
Completion
2018-10-02

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00611572 on ClinicalTrials.gov